NEO1132

Cat. No. M45248

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.

NEO1132 is a novel, orally active dual inhibitor of BET and CBP/EP300 with antitumor activity.

Storage

Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month

Related Epigenetic Reader Domain Products
I-BET151 I-BET151 (GSK1210151A) is an inhibitor of the BET family with IC50 of 0.5 μM, 0.25 μM and 0.79 μM for BRD2, BRD3 and BRD4, respectively.
(+)-JQ1 (+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway.
I-BET-762 I-BET-762 (GSK525762) is a selective small molecule BET inhibitor.
CPI-0610 CPI-0610 is a novel BET protein bromodomain inhibitor.
RVX-208 Apabetalone (RVX-208) is a first-in-class, small molecule inhibitor of BET bromodomain with IC50 of 0.51 μM for BD2.

Catalog